Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Equity Income: 2021-2024

Historic Equity Income for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to -$591,000.

  • Tarsus Pharmaceuticals' Equity Income fell 140.00% to -$6,000 in Q2 2024 from the same period last year, while for Jun 2024 it was -$282,000, marking a year-over-year decrease of 5540.00%. This contributed to the annual value of -$591,000 for FY2024, which is 328.19% down from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' Equity Income is -$591,000, which was down 328.19% from $259,000 recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Equity Income registered a high of $259,000 during FY2023, and its lowest value of -$591,000 during FY2021.
  • Moreover, its 3-year median value for Equity Income was -$268,000 (2022), whereas its average is -$200,000.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Equity Income spiked by 196.64% in 2023, and later plummeted by 328.19% in 2024.
  • Tarsus Pharmaceuticals' Equity Income (Yearly) stood at -$591,000 in 2021, then soared by 54.65% to -$268,000 in 2022, then soared by 196.64% to $259,000 in 2023, then crashed by 328.19% to -$591,000 in 2024.